Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2013, 943014

Opioid Therapy Pharmacogenomics for Noncancer Pain: Efficacy, Adverse Events, and Costs


Opioid Therapy Pharmacogenomics for Noncancer Pain: Efficacy, Adverse Events, and Costs

Yan Xu et al. Pain Res Treat.


Chronic non-cancer pain is a debilitating condition associated with high individual and societal costs. While opioid treatment for pain has been available for centuries, it is associated with high variability in outcome, and a considerable proportion of patients is unable to attain relief from symptoms while suffering adverse events and developing medication dependence. We performed a review of the efficacy of pharmacogenomic markers and their abilities to predict adverse events, dependence, and associated economic costs, focusing on two genes: OPRM1 and CYP2D6. Data sources were articles indexed by PubMed on or before August 6, 2013. Articles were first selected after review of their titles and abstracts, and full papers were read to confirm eligibility. Initially, fifty-two articles were identified. Of these, 17 were relevant to biological actions of pharmacogenomic markers and their effect on therapeutic efficacy, 16 to adverse events, 15 to opioid dependence, and eight to economic costs. In conclusion, increasing costs of opioid therapy have made the advances in pharmacogenomics an attractive solution to personalize care with unclear repercussions related to the impact on costs, morbidity, and outcomes. This intersection of pharmacoeconomics and pharmacogenomics presents a unique platform to further examine current advances in clinical medicine and their utility in cost-effective treatment of chronic pain.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles


    1. Brixner DI, Oderda GM, Roland CL, Rublee DA. Opioid expenditures and utilization in the medicaid system. Journal of Pain and Palliative Care Pharmacotherapy. 2006;20(1):5–13. - PubMed
    1. Guerriere DN, Choinière M, Dion D, et al. The Canadian STOP-PAIN project—part 2: what is the cost of pain for patients on waitlists of multidisciplinary pain treatment facilities? Canadian Journal of Anesthesia. 2010;57(6):549–558. - PubMed
    1. Steglitz J, Buscemi J, Ferguson MJ. The future of pain research, education, and treatment: a summary of the IOM report ‘Relieving pain in America: a blueprint for transforming prevention, care, education, and research’. Translational Behavioral Medicine. 2012;2(1):6–8. - PMC - PubMed
    1. Jackman RP, Purvis JM, Mallett BS. Chronic nonmalignant pain in primary care. American Family Physician. 2008;78(10):1155–1164. - PubMed
    1. Dionne RA, Witter J. NIH-FDA analgesic drug development workshop: translating scientific advances into improved pain relief. Clinical Journal of Pain. 2003;19(3):139–147. - PubMed

LinkOut - more resources